Monsenso signs a new agreement with a leading pharmaceutical company to implement its solution for decentralised patient-centric real-world data collection in a chronic disease area.
Under the new agreement, Monsenso will deliver and support real-world patient data collection for a decentralised patient-centric study expected to take place over the next 12 months.
The agreement and the solution delivered build on Monsenso’s existing platform, which will be customised to support the specific study and the disease of the patient group. It also includes developing new features to support the patient-centric real-world data study, which will position Monsenso’s solution even stronger in the future.
“With this project, we hope to contribute to getting deeper learnings on which treatments work for which patients by continuously engaging and collecting real-world data from patients.
The potential of this engagement is significant – both with the pharmaceutical company itself across other geographies and disease areas as well as with similar companies.” says Thomas Lethenborg, CEO of Monsenso.
The project comes one year into the start of the PhaseV research project, where Monsenso further develops its solution to fully support decentralised real-world data studies and trials in collaboration with leading pharmaceutical companies and research institutions.
Click the button below for more information about the Monsenso solution.